Brooklyn ImmunoTherapeutics Inc (NYSE:BTX - Get Free Report) shares dropped 0.3% during trading on Tuesday . The company traded as low as $7.25 and last traded at $7.32. Approximately 1,486,703 shares changed hands during trading, an increase of 98% from the average daily volume of 751,297 shares. The stock had previously closed at $7.34.
Analyst Ratings Changes
Separately, Wall Street Zen started coverage on Brooklyn ImmunoTherapeutics in a research report on Saturday, May 17th. They set a "hold" rating for the company.
Check Out Our Latest Research Report on BTX
Brooklyn ImmunoTherapeutics Stock Performance
The company's fifty day moving average is $6.91 and its two-hundred day moving average is $4.63. The firm has a market cap of $432.96 million, a price-to-earnings ratio of -3.24 and a beta of 4.61.
About Brooklyn ImmunoTherapeutics
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
See Also
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
